Gujarat Inject Kerala Ltd
APPROVAL OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30.06.2026.
RESULTS
● No Immediate Change
MEDIUM RISK
📅 Filed on BSE: 15 Jul 2026, 10:03 AM IST · BSE ID: f5ed0234-cd29-412b-82b9-1e161a2a4b6d
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board has approved its first quarter financial results for FY27, showing earnings of Rs. 0.86 per share.
🤖 AI Summary
- Gujarat Inject Kerala Ltd Board approved unaudited financial results for Q1 FY27, ended June 30, 2026.
- The Board also took on record the Limited Review Report issued by M/s. S Mandawat & Co., Statutory Auditors.
- Basic earnings per share from continuing and discontinued operations was Rs. 0.86 for Q1 FY27.
- Diluted earnings per share from continuing and discontinued operations was Rs. 0.86 for Q1 FY27.
- The Board meeting, held on July 15, 2026, concluded in 45 minutes.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Basic earnings per share (from continuing and discontinued operations)
Rs. 0.86
Diluted earnings per share (from continuing and discontinued operations)
Rs. 0.86
🏢 How This Affects the Company
The company reported basic earnings per share of Rs. 0.86 and diluted earnings per share of Rs. 0.86 from continuing and discontinued operations for the quarter ended June 30, 2026.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this filing.
👤
Who Is Affected
All shareholders are affected as the company's Q1 FY27 financial performance, specifically earnings per share of Rs. 0.86, impacts the underlying value of their holdings.
🔍
Management Signal
The timely approval and disclosure of quarterly results indicate management's adherence to regulatory compliance and transparency.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 unaudited financial results — for more detailed performance metrics.
Future filings on rebranding and solar focus — for business segment updates.
Annual General Meeting minutes — for any strategic decisions discussed.
MEDIUM RISK
Lack of comprehensive financial data beyond EPS makes a detailed performance assessment challenging.
💡 Investor Takeaway
Gujarat Inject Kerala Ltd reported basic and diluted earnings per share of Rs. 0.86 from continuing and discontinued operations for the quarter ended June 30, 2026. The unaudited results were approved by the Board and reviewed by statutory auditors.
⚖️ Strengths & Concerns
✅ Positives
- Board approval of Q1 FY27 unaudited financial results provides current financial transparency to stakeholders.
- The Limited Review Report issued by statutory auditors, M/s. S Mandawat & Co., confirms auditor oversight.
⚠️ Concerns
- The filing does not provide comparable prior period financial data beyond EPS to assess performance trends.
- Limited detail on revenue, profit, or segmental performance prevents a comprehensive financial analysis.
📅 Company Track Record
Gujarat Inject Kerala Ltd's FY26 revenue was Rs. 36.32 crore, a 91% increase, as per a May 2026 filing. The company previously indicated a rebranding to focus on solar operations.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What were Gujarat Inject Kerala Ltd's earnings per share for Q1 FY27?
Gujarat Inject Kerala Ltd reported basic earnings per share of Rs. 0.86 for the quarter ended June 30, 2026. Diluted earnings per share was also Rs. 0.86.
Which quarter's financial results were approved by Gujarat Inject Kerala Ltd?
The Board of Directors of Gujarat Inject Kerala Ltd approved the unaudited financial results for the first quarter ended on June 30, 2026 (Q1 FY27).
Who reviewed Gujarat Inject Kerala Ltd's Q1 FY27 financial results?
The Q1 FY27 unaudited financial results of Gujarat Inject Kerala Ltd were reviewed by M/s. S Mandawat & Co., Statutory Auditors, who issued a Limited Review Report.
Questions based on this BSE filing only. For information purposes.